Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Srivastava, Alok  [Clear All Filters]
2024
Hwang WYk, Takahashi S, Choi B, Huang H, Kawamata S, Ng SChin, Gupta P, Hamidieh AAli, Koaykul C, Irawan C, et al. Challenges in Global Access to CAR-T cells: an Asian Perspective. Blood Cell Ther. 2024;7(1):10-13.
Srivastava A. Defining success in haemophilia care - Are we doing it right?. Haemophilia. 2024.
Chattopadhyay S, Lionel S, Selvarajan S, Devasia AJ, Korula A, Kulkarni U, Aboobacker FN, Lakshmi KM, Srivastava A, Mathews V, et al. Relapse and transformation to myelodysplastic syndrome and acute myeloid leukemia following immunosuppressive therapy for aplastic anemia is more common as compared to allogeneic stem cell transplantation with a negative impact on survival. Ann Hematol. 2024.
2023
Joshi G, Arthur NBeryl Jane, Geetha TS, Datari PVenkateswa, Modak K, Roy D, Chaudhury ADutta, Sundaraganesan P, Priyanka S, Na F, et al. Comprehensive laboratory diagnosis of Fanconi anaemia: comparison of cellular and molecular analysis. J Med Genet. 2023.
Mahalingam G, Arjunan P, Periyasami Y, Dhyani AKumar, Devaraju N, Rajendiran V, Christopher ACrystal, Kt RDevi, Dhanasingh I, Thangavel S, et al. Correlating the differences in the receptor binding domain of SARS-CoV-2 spike variants on their interactions with human ACE2 receptor. Sci Rep. 2023;13(1):8743.
Young G, Srivastava A, Kavakli K, Ross C, Sathar J, You C-W, Tran H, Sun J, Wu R, Poloskey S, et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. Lancet. 2023.
Srivastava A, Rangarajan S, Kavakli K, Klamroth R, Kenet G, Khoo L, You C-W, Xu W, Malan N, Frenzel L, et al. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2023.
H van den Berg M, Srivastava A. Hemostasis - A Balancing Act. N Engl J Med. 2023;389(9):853-856.
Ikonomou L, Cuende N, Forte M, Grilley BJ, Levine AD, Munsie M, Rasko JEJ, Turner L, Bidkhori HR, Ciccocioppo R, et al. International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products. Cytotherapy. 2023;25(9):920-929.
Balakrishnan B, Illangeswaran RStephen St, Rajamani BMurugan, Arunachalam AKumar, Pai AAnand, Mohanan E, Srivastava A, Mathews V, Balasubramanian P. Metformin pretreatment ameliorates busulfan-induced liver endothelial toxicity during haematopoietic stem cell transplantation. PLoS One. 2023;18(10):e0293311.
Iida M, Liu K, Huang XJun, Huang H, Kuwatsuka Y, Moon JHo, Lee JWook, Lakshmi KM, Dodds A, Wilcox L, et al. Report on hematopoietic cell transplantations performed in 2018/2019 focusing on the trends of selection of stem cell sources in the Asia-Pacific region: APBMT Activity Survey. Blood Cell Ther. 2023;6(4):114-123.
Paul A, Kulkarni U, Yadav B, Aboobacker FN, Devasia AJ, Korula A, Abraham A, George B, George PV, Srivastava A. Speckle tracking echocardiography-derived left ventricular global longitudinal strain in ex-thalassaemics. PLoS One. 2023;18(11):e0293452.
2022
Tokaz MC, Baldomero H, Cowan AJ, Saber W, Greinix H, Koh MBc, Kröger N, Mohty M, Galeano S, Okamoto S, et al. An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Transplant Cell Ther. 2022.
Ravi NSam, Wienert B, Wyman SK, Bell HWilliam, George A, Mahalingam G, Vu JT, Prasad K, Bandlamudi BPrasad, Devaraju N, et al. Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin. Elife. 2022;11.
2021
Maddali M, Kulkarni UPrakash, Ravindra N, Arunachalam AKumar, Venkatraman A, Lionel S, Manipadam MTherese, Devasia AJ, Korula A, Fouzia NA, et al. Mutation profile in BCR-ABL1-negative myeloproliferative neoplasms: A single-center experience from India. Hematol Oncol Stem Cell Ther. 2021.
2020
Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, et al. Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020.
2019
Pasquini MC, Srivastava A, Ahmed SOsman, Aljurf M, Atsuta Y, Doleysh C, Galeano S, Gluckman E, Greinix H, Hale G, et al. Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. Hematol Oncol Stem Cell Ther. 2019.
2018
Kulkarni U, Devasia AJ, Korula A, Na F, Pn N, Samoon YJ, Lakshmi KM, Abraham A, Srivastava A, Mathews V, et al. Use of non-cryopreserved peripheral blood stem cells (PBSC) is associated with adequate engraftment in patients with multiple myeloma undergoing an autologous transplant. Biol Blood Marrow Transplant. 2018.
2015
Chendamarai E, Ganesan S, Alex AAbu, Kamath V, Nair SC, Nellickal AJose, Janet NBeryl, Srivastava V, Lakshmi KM, Viswabandya A, et al. Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance. PLoS One. 2015;10(3):e0121912.
Manian KV, Aalam SMohammed M, Bharathan SP, Srivastava A, Velayudhan SR. Understanding the Molecular Basis of Heterogeneity in Induced Pluripotent Stem Cells. Cell Reprogram. 2015.
2013
Mathews V, George B, Viswabandya A, Abraham A, Ahmed R, Ganapule A, Sindhuvi E, Lakshmi KM, Srivastava A. Improved Clinical Outcomes of High Risk β Thalassemia Major Patients Undergoing a HLA Matched Related Allogeneic Stem Cell Transplant with a Treosulfan Based Conditioning Regimen and Peripheral Blood Stem Cell Grafts. PLoS One. 2013;8(4):e61637.
Viswanathan S, Rao M, Keating A, Srivastava A. Overcoming Challenges to Initiating Cell Therapy Clinical Trials in Rapidly Developing Countries: India as a Model. Stem Cells Transl Med. 2013.